HepaTx and Mayo Clinic Launch Trials for Liver Disease Cell Therapy

​Late-stage liver disease treatment often faces hurdles like organ shortages, high costs, and the risk of tissue rejection. Addressing these issues, biotechnology firm HepaTx, supported by SP Investment Fund, has signed a license agreement with Mayo Clinic to push its stem cell technology into clinical trials.

This partnership targets advancing therapies for liver diseases, beginning with alcohol-related hepatitis, a widespread health issue. Under the agreement, HepaTx will leverage Mayo Clinic’s clinical research expertise to move its proprietary technology from preclinical stages to human trials.

HepaTx’s approach involves using stem cells from adipose tissue to address acute and chronic liver conditions. The collaboration aims to accelerate the transition of HepaTx’s cell therapy into clinical testing, potentially transforming liver disease treatment by advancing innovative therapies with better patient outcomes.

HepaTx CEO Eric Schuur stated his team is committed to working with Mayo Clinic’s experienced researchers to bring these therapies to patients, while Mayo Clinic contributes its specialized expertise in liver disease and regenerative medicine.

SP Investment Fund

Shop